key: cord-0780413-1srqivim
authors: Nguyen, T. P.; Do, Q.; Phan, L. T.; Anh, D. D.; Khong, H.; Dinh, D. V.; Hoang, L. V.; Nguyen, T. V.; Pham, H. N.; Chu, M. V.; Nguyen, T. T.; Le, T. M.; Trang, T. T. N.; Dinh, T. T.; Vo, T. V.; Vu, T. T.; Nguyen, Q. B. P.; Phan, V. T.; Nguyen, L. V.; Nguyen, G. T.; Tran, P. M.; Nghiem, T. D.; Tran, T. V.; Nguyen, T. G.; Tran, T. Q.; Nguyen, L. T.; Do, A. T.; Nguyen, D. D.; Ho, S. A.; Nguyen, V. T.; Pham, D. T.; Tran, H. B.; Vu, S. T.; Hoang, S. X.; Do, T. M.; Nguyen, X. T.; Le, G. Q.; Tran, T.; Cao, T. M.; Dao, H. M.; Nguyen, T. T. T.; Doan, U. Y.; Le, V. T. T.; Tran, L. P.; Nguyen, N. M.; Nguy,
title: The efficacy, safety and immunogenicity Nanocovax: results of a randomized, double-blind, placebo-controlled Phase 3 trial.
date: 2022-03-23
journal: nan
DOI: 10.1101/2022.03.22.22272739
sha: ceddea334db09606950bf3fe56dd02b2b14318e9
doc_id: 780413
cord_uid: 1srqivim

Background Nanocovax is a recombinant severe acute respiratory syndrome coronavirus 2 subunit vaccine composed of full-length prefusion stabilized recombinant SARS-CoV-2 spike glycoproteins (S-2P) and aluminum hydroxide adjuvant. In a Phase 1 and 2 studies, (NCT04683484) the vaccine was found to be safe and induce a robust immune response in healthy adult participants. Methods We conducted a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, immunogenicity, and protective efficacy of the Nanocovax vaccine against Covid-19 in approximately 13,007 volunteers aged 18 years and over. The immunogenicity was assessed based on Anti-S IgG antibody response, surrogate virus neutralization, wild-type SARS-CoV-2 neutralization and the types of helper T-cell response by intracellular staining (ICS) for interferon gamma (IFNg) and interleukin-4 (IL-4). The vaccine efficacy (VE) was calculated basing on serologically confirmed cases of Covid-19. Findings Up to day 180, incidences of solicited and unsolicited adverse events (AE) were similar between vaccine and placebo groups. 100 serious adverse events (SAE) were observed in both vaccine and placebo groups (out of total 13007 participants). 96 out of these 100 SAEs were determined to be unrelated to the investigational products. 4 SAEs were possibly related, as determined by the Data and Safety Monitoring Board (DSMB) and investigators. Reactogenicity was absent or mild in the majority of participants and of short duration. These findings highlight the excellent safety profile of Nanocovax. Regarding immunogenicity, Nanocovax induced robust IgG and neutralizing antibody responses. Importantly, Anti S-IgG levels and neutralizing antibody titers on day 42 were higher than those of natural infected cases. Nanocovax was found to induce Th2 polarization rather than Th1. Post-hoc analysis showed that the VE against symptomatic disease was 51.5% (95% confidence interval [CI] was [34.4%-64.1%]. VE against severe illness and death were 93.3% [62.2- 98.1]. Notably, the dominant strain during the period of this study was Delta variant. Interpretation Nanocovax 25 microgram (mcg) was found to be safe with the efficacy against symptomatic infection of Delta variant of 51.5%.

Nanocovax is a subunit vaccine, developed and manufactured at Nanogen Pharmaceutical Biotechnology JSC., containing the extracellular domain of prefusion stabilized recombinant SARS-CoV-2 S glycoproteins bound to aluminum hydroxide adjuvant.

In rodent and monkey models, Nanocovax induced high levels of Anti-S antibody (Ab) 1 .

Neutralizing antibody titers were evaluated by micro-neutralization assay on the original strain as well as the Delta variant.

In a previous Phase 1 and 2 studies, Nanocovax was found to be safe and induced robust immune responses 2 . Here we report the findings of a randomized, double-blind, placebocontrolled Phase 3 trial started in June 2021, to evaluate the safety, immunogenicity and the VE of 25 mcg recombinant SARS-CoV-2 S glycoprotein in an aluminum adjuvant (0.5 mg/dose) in adults of at least 18 years of age.

The Phase 3 trial was conducted by the Military Medical University (Ha Noi) and the Pasteur Institute in Ho Chi Minh City, at 4 study sites in Vietnam including Hung Yen, Long An, Tien Giang provinces and Ha Noi. This was a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety, immunogenicity, and protective efficacy of the Nanocovax vaccine on Vietnamese volunteers from 18 years of age and older. Eligible participants were men and non-pregnant women, at least 18 years of age with a body mass index (BMI) of 16 to 41 (kg/m 2 ). The participants were stratified into 3 age groups: from 18 to 45 years old, from 46 to 60 years old and over 60 years old ( Table 1 ). The group of over 60 years olds accounted for at least 1,200 participants. 13 ,000 participants were recruited. A subset of the first 1000 participants were evaluated for immunogenicity, in addition to the safety and efficacy (Phase 3a) while the remaining 12,000 participants were followed to evaluate the safety and efficacy of the Nanocovax vaccine (Phase 3b). After enrollment, the first 1000 participants were randomly assigned to either the 'vaccinate' or 'placebo' groups by the Electronic Clinical Data Management (ECDM) system with a ratio of 6 vaccine:1 placebo. The remaining 12,000 were randomly assigned by the ECDM system to either the 'vaccine' or 'placebo' group, in a block of 3 with a ratio of 2 vaccine:1 placebo. All participants received 2 injections of vaccine or placebo on Day 0 and Day 28. Trial staff responsible for the vaccine/placebo administration, as well as participants were unaware of vaccine/placebo assignment. Randomization lists, using block randomization stratified by the study group and study site, were generated by the Electronic Data Capture.

All participants were screened by their medical history, clinical and biological examinations, sampling and laboratory tests (complete blood count, biochemistry, urine analysis, testing pregnancy and diagnostic imaging). Participants with a history of Covid-19 or positive results for SARS-CoV-2 at screening period confirmed by real-time reverse transcriptase polymerase-chain-reaction (RT-PCR) were excluded from the trial. All participants signed a written consent before being enrolled in the trial.

Date cut-off for efficacy analysis was December 13 th , 2021. Intention-to-treat analysis population included participants who had received a first injection. Per-protocol-analysis population included participants receiving 2 injections and those who contracted Covid-19 at least 14 days after the second injection. The safety assessment was conducted on the intentionto-treat population and the immunogenicity assessment was conducted on a subgroup of 1007 participants.

The trials were designed and funded by Nanogen Pharmaceutical Biotechnology JSC and the Ministry of Science and Technology (MOST) of Vietnam. The trial protocol was approved by the Ethics Committee/Protocol Review Board of the Ministry of Health (Vietnam) and was performed in accordance with the ICH-GCP good clinical practice guidelines, with an ethical policy consistent with the "Declaration of Helsinki" and applicable Vietnamese laws and regulations. The authors take responsibility for the data integrity and the fidelity of the trial to the clinical trial protocol.

The recombinant SARS-CoV-2 spike (S) glycoprotein in Nanocovax were constructed with two proline substitutions (K986P and V987P) for stabilized pre-fusion conformation (S-2). The production of the full-length (including the transmembrane domain) recombinant S protein was optimized in a Chinese Hamster Ovary (CHO) cell-expression system. Clinical grade aluminum hydroxide was manufactured by Croda (Denmark). Recombinant SARS-CoV-2 S protein was absorbed to aluminum adjuvant under mild mixing conditions for 18 hours at 2°C to 8°C. The placebo dose was 0.5 mg of sterile aluminum hydroxide. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

On-site safety follow-up time was 60 minutes after each injection. Follow-up visits to evaluate safety were scheduled on days 28, 42, 178 and 358 after vaccination (Table S1 ).

Participants received instructions for self-monitoring and reporting adverse events within 7 days of each vaccination, as facilitated by the use of a diary with pre-defined reactogenicity criteria. Pre-defined local (injection site) reactogenicity included pain, tenderness, erythema and swelling. Pre-defined systemic reactogenicity included fever, nausea or vomiting, headache, fatigue, malaise, myalgia and arthralgia.

The primary safety outcomes were the number and percentage of participants with solicited local and systemic adverse events which occurred within 7 days of vaccination and laboratory results (serum biochemistry and hematology) at days 0, 7, 28 and 42 according to severe, potentially life-threatening, or fatal) and relatedness to the vaccine and placebo. Vital sign measurements were assessed according to the FDA toxicity scoring after vaccination 3 . In addition, participants had nasopharyngeal swab tests for SARS-CoV-2 on the day of screening (Day 0, before the first injection), Day 28 (before the second injection) and any time that they developed symptoms associated with SARS-CoV-2 infection.

All immunological assays were performed at the National Institute of Hygiene and is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

The first primary endpoint was vaccine efficacy (VE) against severe illness and death.

The second primary endpoint was the VE against symptomatic Covid-19 cases with clinical symptoms with onset at least 14 days after the second dose and virologically confirmed results by a RT-PCR test of nasopharyngeal secretions. Symptomatic Covid-19 was defined according to the criteria of the FDA.

The efficacy was assumed to be at least 50%. To determine whether VE was consistent across different subgroups, VE was estimated in each of the following categories, such as age group (from 18 to 45 years old, from 46 to 60 years old and over 60 years old), gender, and protection against severe illness.

The safety was assessed in all participants. Descriptive summary data of participants with solicited/unsolicited systemic and local adverse events (AE), serious adverse events (SAE), medically attended AE and particular events of interests were reported as counts and percentages. For an adverse event that occurred more than once, the analysis was based on only the most severe occurrence and the cause of the event. All serious adverse events were summarized separately. Geometric means (of anti-S IgG concentration and neutralizing antibody titer) and associated 95% confidence intervals (CI) were calculated based on logtransformed data.

The required number of symptomatic Covid-19 events for the primary analysis was at least 69. The primary efficacy end-point was assessed in the per-protocol population and intention to treat population. The VE was defined as the percentage reduction in the hazard ratio between the vaccine and the placebo groups.

The sample size of the Phase 3 study was calculated to test the null hypothesis (H0) VE < 50%. The total number of research subjects selected in the study was expected to be 13,000 participants, with the statistical power 80% and 2 interim analysis (IA) at 35% and 70% of the total target cases using the one-sided O'Brien-Fleming boundary method, assuming the VE was is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 23, 2022. ; https://doi.org/10.1101/2022.03.22.22272739 doi: medRxiv preprint 75%, and the alpha error in the one-sided test was 0.025 in the end-of-term analysis. The study also estimated the percentage of participant excluded from the per-protocol population to be 4% and the attack rate in the placebo group to be 0.1%. VE was defined as the percentage reduction in risk for the primary endpoint (Nanocovax 25 mcg vs placebo). A stratified Cox proportional hazards model was used to evaluate the efficacy of the vaccine versus the placebo.

The study was started on June 11, 2021. Of the 13248 participants screened, 13,007 were recruited and randomized: 8861 received Nanocovax 25 mcg and 4146 received placebo.

Participants were stratified into 3 age groups: from over 18 to 45 years old, from 46 to 60 years old, and over 60 years old ( Figure 1 ). Demographic characteristics of participants in the Phase 3 study are shown in Table 1 . Coexisting conditions of participants were described in table S2.

The incidence of solicited local adverse events in the 7 days after each injection of vaccine and placebo groups were similar ( Figure 2 ). After the first injection, the incidence of pain at the injection site of the vaccine versus the placebo was 40.6 % versus 40.0 %: tenderness: 26.8% versus 26.1%, swelling at the injection site: 0.7% versus 0.8%, redness at the injection site: 0.9% versus 0.9% and pruritus at the injection site: 4.7% versus 5%.

Frequencies of solicited local adverse events after dose 2 were lower than those of dose 1 and were similar in both the Nanocovax 25mcg and placebo groups: pain at the injection site 30.3% versus 26.4% (465/1,764), tenderness 18% versus 13.5%, swelling at the injection site was 0.7% versus 0.4%, redness at the injection site 0.6% versus 0.2% and itching 4.7% versus 5.1%.

After the second injection, the incidence of local pain after vaccine and placebo was 29.6% versus 27.1%, redness: 0.5% versus 0.2%, itching: 5.1% versus 3.3%, tenderness: 17.9% versus 15.2% and swelling/firmness: 0.5% versus 0.3%. Details of solicited local AE after the first and second injections are shown in Table S3 . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Table S4 .

The incidence of unsolicited adverse events was similar among vaccine and placebo groups: 1.68% versus 1.69%, respectively, including hypotension, vestibular disorders, knee pain, hand pain, hyperthyroidism and upper respiratory tract inflammation. Almost all of the unsolicited adverse events were found not to be related to the investigational product and the majority of unsolicited (non-SAE) adverse events in both vaccine and place groups were mild and moderate (Table S5) The participants who experienced Grade 2 anaphylactic reaction, Grade 3 hypertension and COPD were in the vaccine group. All participants recovered completely.

Geometric mean concentration (GMC) of anti-S IgG binding antibody units (BAU/mL) and the associated confidence intervals (CI) 95% were shown. Before the first injection, Anti- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 23, 2022. ;  group was only 0.96 [0·92-1·11] ( Figure 4B ). The vaccine group aged from 18-45 years old had the highest GMFR (269.7), followed by 46-60 year old age group (166.4) and those above 60 years (157.9) ( Figure S2 ). The seroconversion rate was defined as GMFR > 4. On Day 42, the seroconversion rate of the vaccine group was 100% ( Figure S3 ).

Neutralizing antibody was qualitatively and quantitatively evaluated using a surrogate virus neutralization test (sVNT) and plaque reduction neutralization test with serum dilution reducing number of plaques by 50% or higher (PRNT50), respectively. sVNT results were Figure   S6 ). This observation is consistent with the nature of aluminum adjuvants which has been well established for Th2 response induction 5 .

The VE was calculated based on per-protocol population of is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint (Figure 6 ).

The antibody tests allowed some participants to guess the treatment they had received which resulted in them opting out of the trial if they were sero-negative. Fourthly, participants were is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Nanocovax was found to induce both Th1 and Th2 responses with a polarization to Th2.

The Th2 polarization poses a concern of antibody-dependent enhancement (ADE) 6, 26 . This concern has been partially addressed with vaccine studies of hamster models challenged with SARS-CoV-2 as well as the approval of therapeutic antibodies for Covid-19 treatment 27,28 . Importantly, ADE was not observed among patients in the vaccine group of this Nanocovax trial.

This Phase 3 trial has a number of limitations. As mentioned above, the VE analysis encountered multiple challenges: the emergence of Delta variant, the government polices (strict quarantine, vaccine mandate regardless of vaccine trial enrollment) and the difference in Covid-19 survaillance at different study sites. Other limitations are low ethnic diversity (all Vietnamese), small study sized and limited follow-up time. In fact, due to ethical concerns, especially the safety of all participants, the principal investigators, the sponsor, and Ethics Committee decided to terminate the study in December 2022 (1 year of ahead of the projected end date). All participants received emergency use authorized vaccines after this date.

In conclusion, Nanocovax has excellent safety and immunogenicity profile and robust efficacy. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Date cutoff for analysis was December 21, 2021. Intention-to-treat analysis population included participants received 1 st injection. Per-protocol-analysis population included participants receiving 2 injections and those who contracted Covid-19 at least 14 days after the 2nd injection. Safety assessment was conducted on intention-to-treat population. Immunogenicity assessment was conducted on subgroup of 1007 participants. 

Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19

Safety and Immunogenicity of Nanocovax, a SARS-CoV-2 Recombinant Spike Protein Vaccine

Social Science Research Network

Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. US Department of Health and Human Services, Food and Drug Administration

Table for Grading the Severity of Adult and Pediatric Adverse Events. Division of AIDS, National Institute of Health, US Department of Health and

Aluminum adjuvants: preparation, application, dosage, and formulation with antigen

Development and Licensure of Vaccines to Prevent COVID-19; Guidance for Industry. US Department of Health and Human Services, Food and Drug Administration 2020

Effectiveness of COVID-19 vaccines against variants of concern, Canada

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

Effectiveness of Covid-19 Vaccination Against Risk of Symptomatic Infection, Hospitalization, and Death Up to 9 Months: A Swedish Total-Population Cohort Study

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

SARS-CoV-2 variants: levels of neutralisation required for protective immunity

A perspective on potential antibody-dependent enhancement of SARS-CoV-2

FDA authorizes REGEN-COV monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19